| |
|
|
Body weight gain (g) |
Bacterial incidence (mice with positive MRS-C growth/total mice) |
| Group |
Immuno- supressed |
Doses (CFU/mouse) |
Day -4 to 1 |
Day 1 to 6 |
Spleen |
Liver |
MLN |
Blood |
| ICC |
No |
Placebo |
7.3 ± 0.6 |
-0.6 ± 0.6 |
0/8 |
0/8 |
1/8 (24)a |
0/8 |
| ICT |
No |
1·109 |
4.3 ± 0.6 |
1.0 ± 0.4 |
2/8 (6-13)a |
2/8 (12-83)a |
5/8 (94-300)a |
0/8 |
| ISC |
Yes |
Placebo |
7.0 ± 1.0 |
-0.6 ± 0.6 |
0/8 |
2/8 (5-300)a |
1/8 (49)a |
0/8 |
| IST |
Yes |
1·109 |
7.7 ± 0.8 |
-0.5 ± 0.6 |
1/8 (300)a |
1/8 (41)a |
2/8 (12-300)a |
0/8 |
|
| aSamples cross-contaminated with intestinal content. Numbers in parentheses represent the range of bacteria expressed as CFU per organ obtained in 10-diluted bacterial counts in MRS-C agar. |
| Table 2: Results obtained in mice during the acute ingestion study with strain B. longum CECT 7347. Data are the means ± standard deviations of the means (n=8). |
